ARK buys $11.9M of Intellia Therapeutics Inc in a single day
The trade went through ARKK. Plus the other trades that day and how ARK compares with the market.
Generated from ARK's own holdings data.
ARK bought roughly $11.9M of Intellia Therapeutics Inc (NTLA) on 24 Sep 2026, spread across ARKK. No other trade that day was bigger.
Strip out the 9.8% that every holding moved as money left the funds, and NTLA still grew 10%. That excess is what we count as a trade.
It cuts against the month: ARK is still a net seller of Intellia Therapeutics Inc over the last 30 days, by $34.2M across 23 trades.
Everything ARK did on 24 Sep 2026
ARK made 7 real moves that day, once money flowing in and out of the funds is stripped out:
| Stock | Funds | Est. value |
|---|---|---|
| NTLA Intellia Therapeutics Inc | ARKK | +$11.9M |
| TEM Tempus AI Inc | ARKK | −$7.0M |
| SCTX Scribe Therapeutics IncBought 3 days running | ARKG | +$3.8M |
| ARKY Ark Active Autocall Inc ETF | ARKK | +$3.0M |
| BEAM Beam Therapeutics Inc | ARKG | +$1.6M |
| VCYT Veracyte IncBought 3 days running | ARKG | +$916K |
The bigger picture: ARK's last 30 days
Over the last 30 days ARK's biggest net buys have been Meta Platforms Inc ($73.6M), Rocket Lab ($70.3M), Nvidia Corp ($53.0M). Meanwhile the funds have been trimming Advanced Micro Devices ($122.8M), Tempus AI Inc ($65.7M), Twist Bioscience Corp ($46.6M).
Is it working?
ARKK is beating the index this year: +18.0% versus +14.0%.
That five-year gap — 107 points — mostly comes down to timing. Five years ago ARKK was trading close to its all-time high of Feb 2021. It then fell 81% to its low in Dec 2022, and it is still 41% below that peak today. Any comparison that starts near the top of that boom looks brutal.
| To date | 1 month | YTD | 1 year | 5 years |
|---|---|---|---|---|
| ARKK | +5.8% | +18.0% | +11.2% | -21.2% |
| S&P 500 (SPY) | +0.9% | +14.0% | +18.5% | +85.8% |
| Nasdaq-100 (QQQ) | +4.8% | +21.5% | +25.9% | +105.3% |
How we work this out
ETFpeek is an independent research tool and is not affiliated with ARK Invest or Cathie Wood. Figures are estimates from public fund data, shown for information only — not financial advice. Past performance does not indicate future results.